In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Profile of the elderly patient with heart failure admitted to cardiology department

Session Poster Session 1

Speaker Daniel Enriquez Vazquez

Event : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Comorbidities
  • Session type : Poster Session

Authors : D Enriquez Vazquez (Madrid,ES), C Perez Garcia (Madrid,ES), TS Luque Diaz (Madrid,ES), A Travieso Gonzalez (Madrid,ES), V Ruiz Pizarro (Madrid,ES), C Espejo Paeres (Madrid,ES), C Olmos Blanco (Madrid,ES), D Vivas Balcones (Madrid,ES), P Martinez Santos (Madrid,ES), A Esteban (Madrid,ES), J Higueras (Madrid,ES), M Perez Serrano (Madrid,ES), R Bover Freire (Madrid,ES), I Vilacosta (Madrid,ES), C Macaya (Madrid,ES)

Authors:
D Enriquez Vazquez1 , C Perez Garcia1 , TS Luque Diaz1 , A Travieso Gonzalez1 , V Ruiz Pizarro1 , C Espejo Paeres1 , C Olmos Blanco1 , D Vivas Balcones1 , P Martinez Santos1 , A Esteban1 , J Higueras1 , M Perez Serrano1 , R Bover Freire1 , I Vilacosta1 , C Macaya1 , 1Hospital Clinic San Carlos, Cardiovascular Institute - Madrid - Spain ,

Citation:

Background
Prevalence of heart failure (HF) has increased, due to the increased survival of patients. Elderly patient sometimes presents multiple comorbidities that must be taken into account when managing the patient with HF.

Purpose
The objective of this study is to know in depth this subgroup of patients more and more frequent in the usual clinical practice, as well as to study the management that is carried out in them.

Methods
Patients diagnosed with heart failure who were admitted to a cardiology department between July 2016 and March 2017 were registered prospectively and consecutively for one year.

Results
Of 336 patients analyzed, 150 patients were 80 years old or older. Baseline characteristics are summarized in Table 1. Heart rate at discharge was 81.65 vs 69.85 in those under 80 years of age. (p 0.024). In those with reduced LVEF, lower percentage of beta-blockers was used in the elderly patient (70.97% vs 84.26%, p 0.039) as well as ACE inhibitors or ARA2 (56.45% vs 72, 22%; p 0.036) and MRA (38.71% vs 62.04%; p 0.003). Devices use has been significantly lower, with 0% ICD vs 4.9% in the younger age group (p 0.007). Diuretic profile used was different, with greater use of thiazide in the elderly (6.35% vs. 1.83%, p 0.014).

Conclusion
Elderly patient with HF are mostly women, predominantly the group of HFpEF and risk factors. Drugs were used in a lower percentage according to the clinical practice guidelines, and the established objectives, such as the HR, was reached to a lesser extent, and further studies are necessary to determine the reasons for these differences. It is important to know the characteristics of this subgroup due to the increasing prevalence to improve the management of the elderly patient and improve their quality of life as well as prognosis.

Characteristics

Elderly (>80 years)

Younger patients

p value

Mean age

84,69

68,76

<0,001

Male sex

59,3%

38,2%

<0,001

Hypertension

89,3%

75,8%

0,001

Hypercholesterolemia

68%

59,1%

0,094

Smoker

4%

14,5%

0,001

Alcohol consumption

13,9%

1,3%

<0,001

Atrial fibrillation

62,7%

48,4%

0,009

Dependent

22%

10,8%

0,019

Preserved EF

60,66%

44,62%

0,003

Diuretics at admission

69,84%

46,79%

0,003

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are